Sofwave has received NMPA approval to market its ultrasound-based aesthetic platform in mainland China, the company confirmed through a GlobeNewswire release. The clearance opens access to the world's second-largest medical aesthetics market and marks the latest in a series of regulatory wins for the Israeli-founded device company.

NMPA — the National Medical Products Administration of China — serves as the central regulator for medical devices and pharmaceuticals in the country. Securing the designation typically requires submission of clinical and technical data reviewed against standards aligned with international norms, followed by on-site manufacturing audits and product registration certificates. For an aesthetic device company, NMPA clearance functions as a prerequisite for commercial distribution through licensed Chinese distributors, medical aesthetic clinics, and hospital-affiliated dermatology departments.

What does the approval cover?

The press release identifies the approval as covering Sofwave's proprietary ultrasound technology platform, which the company has marketed internationally for facial lifting, wrinkle reduction, and skin tightening indications. The company has previously described the platform as a nonablative approach intended to stimulate dermal remodeling through focused acoustic energy. Specific device parameters — including transducer frequency, focal depth, and treatment energy ranges — were not disclosed in the headline release.

Why does mainland China matter for an aesthetic device?

The Chinese medical aesthetics sector has expanded consistently over the past decade, driven by rising disposable income, increased consumer willingness to undergo noninvasive procedures, and a growing network of licensed clinics in tier-one and tier-two cities. Device-based treatments have outpaced injectables in unit growth in recent reporting cycles, according to industry trackers, though exact market sizing varies across data providers.

For international manufacturers, NMPA clearance typically requires:

• A local Chinese entity or authorized representative
• Clinical evaluation reports referencing either domestic trials or overseas data accepted by NMPA
• Compliance with GB-standard electrical safety and electromagnetic compatibility testing
• Registration of the device classification — most aesthetic energy-based platforms fall under Class II or Class III in China's risk-based framework

Sofwave had previously secured FDA clearance in the United States and CE marking in Europe, allowing commercial use in those jurisdictions. Adding China to that list places the company among a small group of noninvasive ultrasound device manufacturers with three-region regulatory coverage.

What remains undisclosed

The release did not include a launch timeline for the Chinese market, a distribution partner, a pricing structure, or specific clinical endpoints from any supporting study. Sofwave has not publicly detailed whether the NMPA submission relied on data generated outside China or whether a domestic clinical study was conducted. The company also has not yet published, in the materials available, a list of intended treatment indications beyond the general category of aesthetic skin lifting and tightening.

What to watch next

The next indicator of commercial traction will be the announcement of a Chinese distribution partner and an initial clinical training program for operators. Chinese aesthetic regulators require that energy-delivery devices be operated by licensed physicians or under physician supervision, which shapes the commercial pathway for any ultrasound-based platform. The company's regional revenue contribution from mainland China is unlikely to appear in financial disclosures before the second full quarter of active sales.

Industry observers will also track whether Sofwave's clearance triggers competing filings from rival manufacturers in the same device category. NMPA review timelines have lengthened for Class III aesthetic energy devices in 2024–2025, making the Sofwave clearance a useful comparator for regulatory pace. The company has indicated it will share further launch details through future corporate communications.